Knowledge, Perceptions, and Self-Reported Rates of Influenza Immunization among Canadians at High Risk from Influenza: A Cross-Sectional Survey.
adults 18–64 years
adults ≥ 65 years of age
chronic medical conditions
influenza vaccination
vaccination coverage
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
17 Aug 2023
17 Aug 2023
Historique:
received:
16
06
2023
revised:
10
08
2023
accepted:
16
08
2023
medline:
26
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
The Public Health Agency of Canada recommends that 80% of high-risk persons, including adults aged ≥65 years and 18-64 years with certain comorbidities, be vaccinated against influenza. During the 2022-2023 influenza season, we conducted an online survey of 3000 Canadian residents aged ≥18 years randomly recruited from the Léger Opinion (LEO) consumer panel to assess knowledge and perceptions about influenza vaccination as well as survey self-reported vaccination rates. Overall, 47.3% received an influenza vaccination during the 2022-2023 season. Vaccination rates among persons aged 18-64 years with high-risk medical conditions (n = 686) and among adults aged ≥65 years (n = 708) were 46.4% and 77.4%, respectively; 77.8% and 88.5%, respectively, believed influenza vaccination was important for people at high risk from influenza. Only 35.8% of adults aged 18-64 years with comorbidities were aware of being at high risk; 66.0% of this group was vaccinated against influenza, compared with 37.0% of those unaware of being at high-risk. During 2022-2023, 51.3% of people aged ≥65 years and 43.0% of people aged 18-64 years with comorbidities discussed influenza vaccination with healthcare providers. These findings suggest gaps in education regarding the importance of influenza vaccination among people at risk of influenza complications.
Identifiants
pubmed: 37631946
pii: vaccines11081378
doi: 10.3390/vaccines11081378
pmc: PMC10459598
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : CSL Seqirus Inc.
ID : NA
Références
Influenza Other Respir Viruses. 2018 Mar;12(2):232-240
pubmed: 29125689
Health Promot Chronic Dis Prev Can. 2023 Feb;43(2):87-97
pubmed: 36794825
MMWR Recomm Rep. 2022 Aug 26;71(1):1-28
pubmed: 36006864
Lancet Infect Dis. 2010 Feb;10(2):83-92
pubmed: 20113977
Rev Med Virol. 2021 Jul;31(4):e2188
pubmed: 33128859
JAMA Netw Open. 2022 Apr 1;5(4):e228873
pubmed: 35486404
Vaccine. 2022 Jan 24;40(3):503-511
pubmed: 34916102
Clin Infect Dis. 2019 Nov 13;69(11):1845-1853
pubmed: 30715278
J Am Heart Assoc. 2021 Mar 16;10(6):e019636
pubmed: 33719496
Cell Immunol. 2020 Feb;348:103998
pubmed: 31733824